Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Cardillo

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Annals of Neurology|August 1, 1988
The neuropathology of aminergic nuclei in Alzheimer's diseaseR M Zweig, C A Ross, J C Hedreen, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|December 14, 2022
Long-term efficacy (up to 68 weeks) of Baricitinib in combination with topical corticosteroids in adult patients with moderate-to-severe atopic dermatitis: Analysis of treatment responders, partial responders and nonresponders originating from study BREEZE-AD7Jonathan I Silverberg, Eric L Simpson, Jacob Pontoppidan Thyssen, et al.
Circulation. Cardiovascular Interventions|September 26, 2013
Effect on platelet reactivity from a prasugrel loading dose after a clopidogrel loading dose compared with a prasugrel loading dose alone: Transferring From Clopidogrel Loading Dose to Prasugrel Loading Dose in Acute Coronary Syndrome Patients (TRIPLET): a randomized controlled trialJean G Diodati, Jorge F Saucedo, John K French, et al.
The Journal of Rheumatology|September 17, 2018
Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in TreatmentJosef S Smolen, Mark C Genovese, Tsutomu Takeuchi, et al.
Thrombosis and Haemostasis|April 11, 2014
Transferring from clopidogrel loading dose to prasugrel loading dose in acute coronary syndrome patients. High on-treatment platelet reactivity analysis of the TRIPLET trialJ G Diodati, J F Saucedo, T E Cardillo, et al.
The New England Journal of Medicine|March 31, 2016
Baricitinib in Patients with Refractory Rheumatoid ArthritisMark C Genovese, Joel Kremer, Omid Zamani, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 27, 2018
JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a Phase 2 randomized controlled clinical trialKatherine R Tuttle, Frank C Brosius, Sharon G Adler, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Annals of Neurology|August 1, 1988
The neuropathology of aminergic nuclei in Alzheimer's diseaseR M Zweig, C A Ross, J C Hedreen, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|December 14, 2022
Long-term efficacy (up to 68 weeks) of Baricitinib in combination with topical corticosteroids in adult patients with moderate-to-severe atopic dermatitis: Analysis of treatment responders, partial responders and nonresponders originating from study BREEZE-AD7Jonathan I Silverberg, Eric L Simpson, Jacob Pontoppidan Thyssen, et al.
Circulation. Cardiovascular Interventions|September 26, 2013
Effect on platelet reactivity from a prasugrel loading dose after a clopidogrel loading dose compared with a prasugrel loading dose alone: Transferring From Clopidogrel Loading Dose to Prasugrel Loading Dose in Acute Coronary Syndrome Patients (TRIPLET): a randomized controlled trialJean G Diodati, Jorge F Saucedo, John K French, et al.
The Journal of Rheumatology|September 17, 2018
Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in TreatmentJosef S Smolen, Mark C Genovese, Tsutomu Takeuchi, et al.
Thrombosis and Haemostasis|April 11, 2014
Transferring from clopidogrel loading dose to prasugrel loading dose in acute coronary syndrome patients. High on-treatment platelet reactivity analysis of the TRIPLET trialJ G Diodati, J F Saucedo, T E Cardillo, et al.
The New England Journal of Medicine|March 31, 2016
Baricitinib in Patients with Refractory Rheumatoid ArthritisMark C Genovese, Joel Kremer, Omid Zamani, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 27, 2018
JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a Phase 2 randomized controlled clinical trialKatherine R Tuttle, Frank C Brosius, Sharon G Adler, et al.
Pageof 3